← Leaderboards
James Egan
Targagenix, Inc.
$2,284,577
Attributed
$2,284,577
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2M · FY2015–16$2M$1.5M$1M$500K$0
'15
'16
Funding mix
By agency
NIH$2,284,577 · 1
By mechanism
N44$1,984,617 · 1
N43$299,960 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Tumor Specificity”
- David Heimbrook · Leidos Biomedical Research, Inc.$277,736,281
- Gregory H Reaman · National Childhood Cancer Foundation$159,328,537
- Richard A Gibbs · Baylor College Of Medicine$84,007,224
- Jan C Buckner · Mayo Clinic Coll Of Medicine, Rochester$82,030,599
- Meenhard Herlyn · University Of Pennsylvania$77,052,837
- Larry Arthur$76,676,783
Research focus
Tumor SpecificityAnalytical MethodBaseBiodistributionCancer PatientCancer Stem CellCell LineClinicClinical TrialsCytotoxic AgentCytotoxicityDosage FormsDoseTime UseToxicologyAdverse EffectsDrug KineticsExhaustInvestigationIn VitroIn VivoKillingsMalignant NeoplasmsMulti-Drug Resistance
Grant awards (2)
IGF::OT::IGF R&D- NANOEMULSION FORMULATION AND IND-ENABLING STUDIES OF A NOVEL CENTER STEM CELL CYTOTOXIC AGENT$1,984,617
N44 · FY2016 · CA · contact PI
IGF::OT::IGF R&D- NANOEMULSION FORMULATION AND IND-ENABLING STUDIES OF A NOVEL CENTER STEM CELL CYTOTOXIC AGENT$299,960
N43 · FY2015 · CA · contact PI